---
id: antimicrobials_ripe-therapy-tb_036
category: antimicrobials
tags: [antimicrobials, tuberculosis, RIPE, rifampin, isoniazid, pyrazinamide, ethambutol]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## RIPE Therapy for Drug-Susceptible Tuberculosis

**Q:** What is RIPE therapy for tuberculosis, what is the standard dosing and duration, and when should treatment be extended?

**A:**

**RIPE Acronym:**
- **R**ifampin
- **I**soniazid
- **P**yrazinamide
- **E**thambutol

**Standard 6-Month Regimen (Drug-Susceptible TB):**

| **Phase** | **Duration** | **Drugs** | **Frequency** |
|-----------|--------------|-----------|---------------|
| **Intensive** | 2 months | RIPE (all 4) | Daily |
| **Continuation** | 4 months | RI (rifampin + isoniazid) | Daily |

**Total:** 6 months for drug-susceptible pulmonary TB

**Newer 4-Month Regimen (2024 Update):**
- Isoniazid + **Rifapentine** + Moxifloxacin + Pyrazinamide x 4 months
- For ages â‰¥12 years with drug-susceptible pulmonary TB
- Noninferior to 6-month regimen
- Conditionally recommended (IDSA/ATS/CDC 2024)

**When to Extend Treatment to 9 Months:**
- **Cavitary disease** on CXR AND
- **Culture-positive** at 2 months
- Also for **CNS TB**, **bone/joint TB**, **miliary TB**

**Dosing (Weight-Based):**

| **Drug** | **Daily Dose (mg/kg)** | **Max Daily Dose** |
|----------|------------------------|-------------------|
| Rifampin | 10 | 600 mg |
| Isoniazid | 5 | 300 mg |
| Pyrazinamide | 25-30 (intensive) | 2000 mg |
| Ethambutol | 15-20 (intensive) | 1600 mg |

**Mnemonic: "RIPE for 2, then RI for 4"**
- **RIPE** = All 4 drugs
- **2** months intensive
- **RI** = Rifampin + Isoniazid only
- **4** months continuation
- **Total: 6 months** (or 9 if cavitary + culture-positive at 2 months)

**Clinical Pearls:**
- Give **pyridoxine (vitamin B6) 25-50 mg daily** with isoniazid to prevent peripheral neuropathy
- Check **baseline and monthly LFTs** (hepatotoxicity risk with RIF, INH, PZA)
- Check **baseline and monthly vision/color** with ethambutol (optic neuritis)
- **Directly observed therapy (DOT)** recommended for all phases

**Media:** None

**Sources:** [CDC TB Treatment Guidelines 2024], [IDSA/ATS/ERS/CDC Clinical Practice Guideline 2025 Update], [StatPearls 2024 - Antitubercular medications], [Johns Hopkins ABX Guide - Active TB], [Medscape TB Treatment 2024]
